Source link : https://www.newshealth.biz/health-news/no-qol-downside-with-adding-nivo-to-chemo-in-urothelial-cancer/
BARCELONA, Spain — Health-related quality of life (HRQoL) is not further compromised by the addition of nivolumab (Opdivo) immunotherapy to first-line cisplatin-based chemotherapy in patients with unresectable or metastatic urothelial carcinoma, according to an analysis of a phase 3 randomized trial. Jens Bedke, MD, presented this and other findings of the analysis of CheckMate 901 […]
Author : News Health
Publish date : 2024-09-18 12:51:41
Copyright for syndicated content belongs to the linked Source.
Categories